Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14423328 | 0.72 | — | — | |
| SCHEMBL21474602 | 0.67 | — | — | |
| SCHEMBL1747877 | 0.67 | CYP2A13 (0.30) | CYP2A13 | |
| SCHEMBL16033512 | 0.67 | CYP2C9 (0.41) | CYP2A13 | |
| Hydrochloric Acid SCHEMBL1761554 | 0.65 | — | — | |
| SCHEMBL455607 | 0.65 | CYP2C9 (0.33) | — | |
| SCHEMBL13211372 | 0.63 | KDM4E (0.32) | KDM4ETDP1 | |
| SCHEMBL678774 | 0.63 | — | — | |
| SCHEMBL7479191 | 0.63 | — | — | |
| SCHEMBL8683172 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11213518-B2 | Ligands of the mu, kappa, and delta opioid receptors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-01-04 | — | — | US | disclosed |
| US-10071982-B2 | Method of treating neuropathic pain | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2018-09-11 | — | — | US | disclosed |
| US-20160340335-A9 | METHOD OF TREATING NEUROPATHIC PAIN | UNIVERSITY OF UTAH (US) | 2016-11-24 | — | — | US | disclosed |
| US-20140011836-A1 | METHOD OF TREATING NEUROPATHIC PAIN | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-01-09 | — | — | US | disclosed |
| US-8034940-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-11 | — | — | US | disclosed |
| US-20100173937-A1 | USE OF TETRAKIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-07-08 | — | — | US | disclosed |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213518-B2 | Ligands of the mu, kappa, and delta opioid receptors | OPRK1, OPRD1, OPRM1 | KDM4E 3058/4885TDP1 3285/4885CYP2A13 927/4885 |
| US-10071982-B2 | Method of treating neuropathic pain | INA, GAP43, ACHE | KDM4E 2168/4885TDP1 2886/4885CYP2A13 4533/4885 |
| US-20160340335-A9 | METHOD OF TREATING NEUROPATHIC PAIN | INA, GAP43, ACHE | KDM4E 2168/4885TDP1 2886/4885CYP2A13 4533/4885 |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFKB2, NFRKB, NFKB1 | KDM4E 1666/4885TDP1 2694/4885CYP2A13 762/4885 |
| US-20100173937-A1 | USE OF TETRAKIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | CACNA1I, TRPA1, KCNN3 | KDM4E 2058/4885TDP1 1200/4885CYP2A13 4767/4885 |
| US-20140011836-A1 | METHOD OF TREATING NEUROPATHIC PAIN | INA, GAP43, ACHE | KDM4E 2168/4885TDP1 2886/4885CYP2A13 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.